An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific
Systemic lupus erythematosus (SLE; MONDO:0007915) is a systemic autoimmune disorder with heterogeneous organ involvement and a core immunologic theme of loss of tolerance to ubiquitous nuclear antigens.[medgen-6146-sle][crispin-2010-pathogenesis-human-sle] As summarized in a mechanistic review, "SLE is a systemic autoimmune disorder driven by an immune response directed against ubiquitous, mostly intranuclear, self-antigens," and patients can manifest "skin rash, photosensitivity" and other systemic features.[crispin-2010-pathogenesis-human-sle] The disease course is shaped by autoantibodies, immune complex formation, innate immune activation, and tissue-damaging inflammatory cascades that link molecular triggers to clinical phenotypes.[obermoser-2010-interferon-alpha-signature][crispin-2010-pathogenesis-human-sle]
A recurring early step is defective handling of self-antigens derived from dying cells. In SLE, "apoptotic material and production of autoantibodies have long been recognized as major pathogenic events in this disease," emphasizing the connection between self-antigen exposure and autoimmunity.[obermoser-2010-interferon-alpha-signature] Consistent with this, disturbances in cell death and clearance are mechanistically important; one review notes that "Disturbances in apoptosis and/or clearance of apoptotic cells can play an important role in the pathogenesis of SLE."[crispin-2010-pathogenesis-human-sle]
Type I interferon (IFN) pathways form a central amplification loop. Plasmacytoid dendritic cells are highlighted as critical innate sensors because "pDCs ... are the main source of type I interferon (IFN) cytokines, which contribute to the immunopathogenesis of SLE."[kim-2015-pdc-ifn-axis-sle] This fits with the broader observation that "the type I interferon cytokine family has been postulated to play a central role in SLE pathogenesis," linking nucleic acid recognition to systemic immune activation.[obermoser-2010-interferon-alpha-signature]
Transcriptomic studies in blood reinforce the centrality of interferon programs and myeloid signatures. One study reported that the IFN gene expression "signature" served as a marker for more severe disease involving the kidneys, hematopoetic cells, and/or the central nervous system.[baechler-2003-interferon-signature-severe-sle] Another found that active SLE shows overexpression of granulopoiesis-related and IFN-induced genes and that immature neutrophils are present in many patients, indicating a granulopoiesis signature linked to disease activity.[bennett-2003-interferon-granulopoiesis-signature]
Complement biology adds an additional axis of susceptibility and tissue injury. Classical pathway deficiency is strongly associated with disease, with a review noting that "deficiency of early complement proteins from the classical pathway ... is strongly associated with development of systemic lupus erythematosus (SLE)."[macedo-2016-complement-classical] Complement and Fc receptor-mediated handling of immune complexes thereby influences both tolerance and end-organ inflammation.[macedo-2016-complement-classical]
Neutrophil extracellular traps (NETs) are another source of nuclear autoantigens and inflammatory signals. NETs are described as "web-like structures composed of chromatin backbones and granular molecules," and "an imbalance between NET formation and clearance in SLE patients may play a prominent role in the perpetuation of autoimmunity and the exacerbation of disease."[kaplan-2013-nets-sle] This integrates neutrophil biology into the self-amplifying cycles of autoantigen exposure and interferon-driven activation.
Neutrophil heterogeneity further refines this axis. A systems analysis notes that "SLE is characterized by elevated levels of a pathogenic neutrophil subset known as low-density granulocytes (LDGs)" and highlights functional diversity among neutrophil subsets.[li-2019-neutrophil-diversity-sle] A comprehensive review adds that "LDNs in SLE can secrete increased levels of type I interferon (IFN)" and readily form NETs, linking neutrophil subsets to IFN amplification and tissue damage.[carriere-2020-low-density-neutrophils-sle]
Endosomal nucleic-acid sensing via TLR7 and TLR9 is differentially regulated in SLE. In pDCs, TLR7-mediated IFN-alpha production is up-regulated and correlates with disease activity, whereas TLR9-mediated IFN-alpha production is down-regulated, indicating asymmetric tuning of these pathways.[takeda-2018-tlr7-ifn-pdc-sle] In B cells, TLR9 responses are impaired, with defective upregulation of activation molecules and diminished cytokine production, and this defect is restricted to B cells rather than pDCs, suggesting loss of TLR9 tolerogenic function contributes to the break of B cell tolerance.[mahdavi-2018-tlr9-bcells-sle]
Mitochondrial stress and oxidized mitochondrial DNA (mtDNA) provide an additional source of interferogenic nucleic acids. In a primary study of NETosis, "release of oxidized mitochondrial DNA is proinflammatory in vitro" and "stimulates type-I interferon (IFN) signaling through a pathway dependent on the DNA sensor, STING."[campbell-2016-oxidized-mtdna-nets-sle] Complementary evidence shows that "Mitochondrial stress releases mitochondrial DNA (mtDNA) into the cytosol and triggers the type-I interferon (IFN) response" and that mtDNA fragments are released "via pores formed by the voltage-dependent anion channel (VDAC) oligomers" in the mitochondrial outer membrane.[liu-2019-vdac-mtdna-lupus]
Defective extracellular DNA degradation can further fuel autoreactivity. In a primary study, "SLE patients with nephritis manifested reduced DNASE1L3 activity in circulation, which was associated with neutralizing autoantibodies to DNASE1L3," directly linking nuclease impairment to lupus nephritis and immune activation.[hartl-2021-dnase1l3-autoantibodies]
Genetic susceptibility spans immune recognition, signaling, and clearance pathways. A genomic-era review reports "more than 30 robust genetic associations with SLE including genetic variants of HLA and Fc gamma receptor genes, IRF5, STAT4, PTPN22, TNFAIP3, BLK, BANK1, TNFSF4 and ITGAM."[deng-2011-genetic-susceptibility-sle] These translate into key gene annotations such as IRF5 (HGNC:6120), STAT4 (HGNC:11365), PTPN22 (HGNC:9652), TNFAIP3 (HGNC:11896), BLK (HGNC:1057), BANK1 (HGNC:18233), TNFSF4 (HGNC:11934), ITGAM (HGNC:6149), and Fc gamma receptor genes FCGR2A (HGNC:3616) and FCGR2B (HGNC:3618), all implicated in immune signaling and tolerance in SLE.[deng-2011-genetic-susceptibility-sle]
Complement-associated genes are also central, reflecting the strong disease association of classical pathway deficiency: C1QA (HGNC:1241), C1QB (HGNC:1242), C1QC (HGNC:1245), C2 (HGNC:1248), and C4A/C4B (HGNC:1323/1324) underpin immune complex clearance and tolerance.[macedo-2016-complement-classical] Nuclease-mediated clearance of extracellular DNA involves DNASE1L3 (HGNC:2959), which is functionally impaired in a substantial subset of patients with nephritis.[hartl-2021-dnase1l3-autoantibodies] Innate nucleic-acid sensing by endosomal receptors contributes to the interferon program; pDCs recognize nucleic acids through TLR7 (HGNC:15631) and TLR9 (HGNC:15633), which links nucleic acid exposure to IFN production in SLE.[kim-2015-pdc-ifn-axis-sle]
BAFF signaling provides a bridge between T cell activation and autoreactive B cell expansion. In active SLE, CD4+ and CD8+ T cells express BAFF (TNFSF13B; HGNC:11929), and the authors conclude that "BAFF may play a pathogenic role in SLE by stimulating T cell-dependent B cell autoantibodies production."[zhang-2007-baff-tcells-sle] BAFF receptors including TACI (TNFRSF13B; HGNC:18153) and BAFF-R (TNFRSF13C; HGNC:17755) are expressed on B cells, and blockade with TACI-Ig suppresses spontaneous anti-dsDNA production in active SLE with kidney involvement, linking BAFF to pathogenic autoantibody generation.[zhang-2007-baff-tcells-sle] Altered B cell signaling components also emerge in TLR9-defective B cells, including decreased expression of the CD19/CD21 complex (CD19 HGNC:1633; CR2 HGNC:2336), underscoring disrupted B cell regulatory circuits.[mahdavi-2018-tlr9-bcells-sle]
Mitochondrial pathways implicated in lupus include VDAC1 (HGNC:12669), where VDAC oligomerization controls mtDNA release and downstream IFN signaling in lupus-like disease models.[liu-2019-vdac-mtdna-lupus]
Relevant chemical entities include nucleic acids that act as autoantigens and innate immune ligands: deoxyribonucleic acid (DNA; CHEBI:16991) and ribonucleic acid (RNA; CHEBI:33697) as well as the cGAS-STING second messenger 2'-3'-cGAMP (CHEBI:75947) implicated in DNA-sensing pathways.[kim-2015-pdc-ifn-axis-sle][thim-2020-sting-lupus] The antimalarial immunomodulator hydroxychloroquine (CHEBI:5801) is relevant in SLE studies of TLR9 function, where defective responses were reported in B cells from patients without hydroxychloroquine treatment.[mahdavi-2018-tlr9-bcells-sle]
Evidence items with PMIDs anchoring these mechanistic claims include 20138006 (apoptotic clearance and lupus pathogenesis), 20693194 (type I IFN signature), 26110387 (pDC-IFN axis), 26941740 (complement deficiency), 24244889 (NETs), 33783474 (DNASE1L3 autoantibodies), 21060334 (genetic susceptibility), 23929771 and 25014039 (lupus nephritis), 12604793 and 12642603 (interferon and granulopoiesis signatures), 30210502 and 29515028 (TLR7/9 dysregulation), 17500077 (BAFF in T cells), 26779811 (oxidized mtDNA NETs), 31857488 (VDAC-mediated mtDNA release), 31754025 (neutrophil diversity and LDGs), 32524751 (LDNs in SLE), and 33083760 (STING-mediated lupus in vivo).[crispin-2010-pathogenesis-human-sle][obermoser-2010-interferon-alpha-signature][kim-2015-pdc-ifn-axis-sle][macedo-2016-complement-classical][kaplan-2013-nets-sle][hartl-2021-dnase1l3-autoantibodies][deng-2011-genetic-susceptibility-sle][lech-2013-lupus-nephritis][schwartz-2014-lupus-nephritis-pathogenesis][baechler-2003-interferon-signature-severe-sle][bennett-2003-interferon-granulopoiesis-signature][takeda-2018-tlr7-ifn-pdc-sle][mahdavi-2018-tlr9-bcells-sle][zhang-2007-baff-tcells-sle][campbell-2016-oxidized-mtdna-nets-sle][liu-2019-vdac-mtdna-lupus][li-2019-neutrophil-diversity-sle][carriere-2020-low-density-neutrophils-sle][thim-2020-sting-lupus]
Core dysregulated biological processes include type I interferon-mediated signaling (GO:0060337), B cell activation (GO:0042113), T cell activation (GO:0042110), classical pathway complement activation (GO:0006958), apoptotic cell clearance (GO:0043277), neutrophil extracellular trap formation (GO:0140645), toll-like receptor 7 signaling pathway (GO:0034154), toll-like receptor 9 signaling pathway (GO:0034162), and myeloid cell differentiation (GO:0030099), all of which are repeatedly implicated across mechanistic studies and reviews.[obermoser-2010-interferon-alpha-signature][kim-2015-pdc-ifn-axis-sle][macedo-2016-complement-classical][crispin-2010-pathogenesis-human-sle][kaplan-2013-nets-sle][takeda-2018-tlr7-ifn-pdc-sle][mahdavi-2018-tlr9-bcells-sle][bennett-2003-interferon-granulopoiesis-signature]
The principal cellular participants include plasmacytoid dendritic cells (CL:0000784), B cells (CL:0000236), CD4-positive helper T cells (CL:0000492), neutrophils (CL:0000775), monocytes (CL:0000576), macrophages (CL:0000235), and plasma cells (CL:0000786), which together integrate innate sensing with adaptive autoantibody production.[kim-2015-pdc-ifn-axis-sle][crispin-2010-pathogenesis-human-sle][kaplan-2013-nets-sle] Key cellular components and compartments include endosomes (GO:0005768) for TLR7/9 sensing, cytosolic DNA-sensing pathways involving cGAS-STING, nuclear reservoirs of autoantigens, mitochondria (GO:0005739) including the mitochondrial outer membrane (GO:0005741) where VDAC oligomers release mtDNA, and extracellular space (GO:0005615) where immune complexes and NETs accumulate and trigger complement activation.[kim-2015-pdc-ifn-axis-sle][thim-2020-sting-lupus][kaplan-2013-nets-sle][macedo-2016-complement-classical][liu-2019-vdac-mtdna-lupus] The granulopoiesis signature in active SLE also points to altered myeloid development in bone marrow (UBERON:0002371), consistent with the presence of immature neutrophils in peripheral blood.[bennett-2003-interferon-granulopoiesis-signature]
A plausible mechanistic sequence begins with genetic susceptibility to immune dysregulation and clearance defects.[deng-2011-genetic-susceptibility-sle] Environmental or endogenous triggers increase cell death and the release of nuclear antigens, while defective apoptotic and extracellular DNA clearance allows these ligands to persist.[crispin-2010-pathogenesis-human-sle][hartl-2021-dnase1l3-autoantibodies] Nucleic acid-rich material and immune complexes stimulate pDCs and endosomal TLR7/9, promoting a sustained type I IFN program that is skewed toward enhanced TLR7 and reduced TLR9 responses.[kim-2015-pdc-ifn-axis-sle][obermoser-2010-interferon-alpha-signature][takeda-2018-tlr7-ifn-pdc-sle][mahdavi-2018-tlr9-bcells-sle] Mitochondrial stress and VDAC-dependent mtDNA release further amplify cytosolic DNA sensing and type I IFN signaling.[campbell-2016-oxidized-mtdna-nets-sle][liu-2019-vdac-mtdna-lupus] IFN-driven activation of B and T cells feeds autoantibody production, which is further supported by BAFF signaling and leads to immune complex formation and complement activation, culminating in tissue deposition and inflammation.[obermoser-2010-interferon-alpha-signature][macedo-2016-complement-classical][zhang-2007-baff-tcells-sle] NETosis provides an additional source of extracellular chromatin that sustains this loop, particularly in LDG/LDN subsets.[kaplan-2013-nets-sle][li-2019-neutrophil-diversity-sle][carriere-2020-low-density-neutrophils-sle] In parallel, cGAS-STING signaling can promote dendritic cell activation and lupus-like disease in vivo, indicating a cytosolic DNA-sensing axis that may reinforce the interferon circuit.[thim-2020-sting-lupus]
The systemic autoimmune phenotype (HP:0002725) manifests across multiple tissues, consistent with widespread exposure to nuclear autoantigens and immune complex-mediated inflammation.[crispin-2010-pathogenesis-human-sle][obermoser-2010-interferon-alpha-signature] Gene-expression data indicate that the IFN signature is associated with severe disease involving kidneys, hematopoetic cells, and the central nervous system (UBERON:0001017), providing a molecular link between interferon biology and organ involvement.[baechler-2003-interferon-signature-severe-sle] Cutaneous involvement is common in skin (UBERON:0002097), and SLE patients can exhibit skin rash, cutaneous photosensitivity (HP:0000992), and malar rash (HP:0025300).[crispin-2010-pathogenesis-human-sle] Musculoskeletal involvement includes arthritis (HP:0001369), reflecting immune activation and inflammatory cascades.[crispin-2010-pathogenesis-human-sle] Hematologic manifestations include hemolytic anemia (HP:0001878), thrombocytopenia (HP:0001873), and decreased total leukocyte count (HP:0001882), consistent with systemic immune activation and granulopoiesis signatures.[crispin-2010-pathogenesis-human-sle][bennett-2003-interferon-granulopoiesis-signature] Neurologic involvement can include seizures (HP:0001250), aligning with central nervous system involvement in severe disease.[crispin-2010-pathogenesis-human-sle][baechler-2003-interferon-signature-severe-sle]
Renal disease is a central end-organ manifestation. Lupus nephritis occurs in kidney (UBERON:0002113), particularly in the renal glomerulus (UBERON:0000074), and is characterized clinically by nephritis (HP:0000123) and proteinuria (HP:0000093).[lech-2013-lupus-nephritis][schwartz-2014-lupus-nephritis-pathogenesis] Mechanistically, "Lupus nephritis is an immune complex GN that develops as a frequent complication of SLE," linking autoantibody-immune complex formation to glomerular injury.[lech-2013-lupus-nephritis] Impaired DNA clearance (e.g., DNASE1L3 neutralization) is enriched in patients with nephritis, providing a mechanistic bridge between nucleic acid-driven autoimmunity and renal damage.[hartl-2021-dnase1l3-autoantibodies]
A major open question is how distinct sources of self-nucleic acids (apoptotic debris versus NET-derived chromatin versus microparticle-associated DNA) differentially drive interferon programs and organ tropism in human SLE.[crispin-2010-pathogenesis-human-sle][kaplan-2013-nets-sle][hartl-2021-dnase1l3-autoantibodies] Another unresolved issue is the hierarchy of innate sensors in patient subsets, whether endosomal TLR7/9 or cytosolic cGAS-STING pathways dominate in specific clinical phenotypes and how this relates to genetic background or treatment response.[kim-2015-pdc-ifn-axis-sle][thim-2020-sting-lupus] Finally, the precise mechanisms by which classical pathway complement deficiencies and Fc receptor variants skew tolerance and immune complex handling in vivo remain incompletely mapped, particularly in the transition from systemic autoimmunity to organ-specific injury.[macedo-2016-complement-classical][deng-2011-genetic-susceptibility-sle]
Pathophysiology description (current understanding) Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease driven by breakdown of immune tolerance, chronic activation of innate nucleic acid–sensing pathways (especially the type I interferon axis), aberrant B- and T-cell help, impaired clearance of apoptotic and NETotic debris, and complement pathway perturbations leading to immune complex deposition and organ inflammation (kidney, skin, CNS, vasculature). Contemporary reviews highlight a unifying framework that integrates type I IFN signaling, TLR7/9-driven autoreactivity, neutrophil extracellular traps (NETs) and oxidative stress, B cell extrafollicular and germinal-center responses (including age-associated B cells, ABCs), and tissue injury mediated by immune complexes and complement activation (Oct 2024; https://doi.org/10.3390/ijms252010905) (moysidou2024lymphocyteschangetheir pages 18-20). NETs are now recognized as amplifiers of the pDC–TLR9–IFN-α loop and as sources of modified autoantigens; “impaired NET catabolism due to deficient serum DNase1 is associated with renal involvement,” while NET DNA–peptide complexes can protect nucleic acids from degradation and activate pDCs to produce IFN-α (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (yuan2024globalresearchtrends pages 10-10).
Key mechanistic axes - Type I interferon signature: An IFN-I–inflamed milieu is present in a majority of patients and shapes dysregulation across immune cell lineages. Stratified analyses link elevated IFN gene signatures and chemokines (e.g., CXCL10/CXCL13) to clinical phenotypes and therapy responses; notably, “High IFN gene signature [is associated with] favorable response to anifrolumab therapy” (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - Nucleic-acid sensing via endosomal TLRs: B cell–intrinsic TLR7 signaling is a central driver of lupus pathology, whereas TLR9 can exert counter-regulatory effects; genetic and mechanistic data show that when TLR9 is absent, unrestrained TLR7 signaling worsens disease (2024; dissertation/manuscript synthesis) (cosgrove2024tolllikereceptor7 pages 160-164). As one concise conclusion from this body of work: “B cell–intrinsic TLR7 drives severe lupus,” and NOX2 (CYBB)–dependent ROS can negatively regulate TLR7–NF-κB signaling (cosgrove2024tolllikereceptor7 pages 160-164). - Impaired clearance and complement: Defective apoptotic cell clearance and complement deficiencies increase exposure to nuclear antigens, propagate immune complex formation, and correlate with lupus nephritis; early-component complement defects (e.g., C1q) and impaired NET degradation are linked to renal injury and complement activation (Oct 2024; https://doi.org/10.3390/ijms252010905; Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - B–T collaboration and tolerance failure: Extrafollicular and GC pathways are both implicated. T follicular helper–like cells (ICOS+, PD-1+, IL-21+) expand and drive autoreactive B-cell differentiation; murine and human data show that blocking Tfh development ameliorates disease (Jul 2025; https://doi.org/10.3390/cells14141080) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). Age-associated B cells (ABCs; CD11c+, T-bet+) are enriched in SLE and correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z; 2024 mechanistic synthesis) (wu2025immunecellaberrations pages 29-30, cosgrove2024tolllikereceptor7 pages 160-164). - NETosis and oxidative stress: NETs fuel IFN-α production, directly activate autoreactive B cells, and trigger complement; oxidative stress and defective NET clearance amplify this loop (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350; Oct 2024; https://doi.org/10.3390/ijms252010905) (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Neurovascular and CNS injury: Neuropsychiatric SLE reflects composite mechanisms (vasculopathy, microthrombi, inflammatory mediators) superimposed on systemic autoimmunity; “no single laboratory test is currently available to definitively confirm the diagnosis of NPSLE,” emphasizing mechanistic heterogeneity (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).
Direct supporting statements (selected quotes) - “Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis… NETs… protect DNA from degradation, enabling activation of plasmacytoid dendritic cells (pDCs) through TLR9 and driving IFN-α production.” (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (yuan2024globalresearchtrends pages 10-10). - “High IFN gene signature [→] favorable response to anifrolumab therapy,” underscoring mechanism-based stratification (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - “B cell–intrinsic TLR7 drives severe lupus… [and] TLR9 can restrain differentiation of age/autoimmune-associated B cells and plasmablasts,” highlighting TLR7/9 counterpoints (2024; mechanistic synthesis) (cosgrove2024tolllikereceptor7 pages 160-164). - “No single laboratory test is currently available to definitively confirm the diagnosis of NPSLE,” reflecting complex pathophysiology (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).
Key molecular players - Genes (HGNC): - TLR7 (HGNC:15631) – B cell–intrinsic driver; promotes RNA-associated autoantibodies and disease; counterbalanced by TLR9 (cosgrove2024tolllikereceptor7 pages 160-164). - MYD88 (HGNC:7562) – adaptor downstream of TLR7/9, required in B cells for autoantibody production and glomerulonephritis in models (conceptual synthesis) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - CYBB (NOX2; HGNC:2553) – NOX2-generated ROS negatively regulate TLR7 NF-κB signaling; loss exaggerates disease (cosgrove2024tolllikereceptor7 pages 160-164). - Cytokines/ligands (UniProt/protein classes): - IFN-α (type I interferon) – signature pathway with clinical and therapeutic implications (wu2025immunecellaberrations pages 29-30). - BAFF (TNFSF13B) – supports B-cell survival and extrafollicular responses; integrated with IFN/Tfh circuits (wu2025immunecellaberrations pages 29-30, zhou2024cartcelltherapy pages 4-4). - IL-21 – Tfh-derived; drives B-cell differentiation to plasma cells; Tfh IL-21 blockade ameliorates disease in models (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, zhou2024cartcelltherapy pages 4-4). - Autoantibodies: ANA, anti-dsDNA, anti-Sm; anti-C1q associated with nephritis activity; immune complexes underlie type III injury and complement consumption (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4, moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - Complement (components/regulators): C1q/C3/C4 perturbations and complement activation/consumption integrate with immune complexes and NET persistence (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10).
Cell types (CL ontology exemplars) - Plasmacytoid dendritic cells (pDCs; CL:0000784) – principal IFN-α producers downstream of NET DNA/RNA and TLR9/TLR7 ligation (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - B cells (CL:0000236); age-associated B cells (ABCs; CL subclass) – enriched, T-bet/CD11c+ phenotypes; extrafollicular activation; autoantibody production (wu2025immunecellaberrations pages 29-30, cosgrove2024tolllikereceptor7 pages 160-164). - T follicular helper cells (Tfh; CL:0002038) and T peripheral helper cells (Tph) – IL-21/ICOS/PD-1+ subsets that support autoreactive B cells (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, zhou2024cartcelltherapy pages 4-4). - Neutrophils and low-density granulocytes (LDGs; CL:0000096 variant) – heightened NETosis and oxidant stress; impaired NET clearance (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - Cytotoxic/effector T cells – contribute to tissue injury and, in NPSLE, inflammatory milieu and vascular injury (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4, moysidou2024lymphocyteschangetheir pages 18-20).
Anatomical locations/organs (UBERON) - Kidney/glomerulus (UBERON:0002113/0000071) – immune complex GN, NET/complement interplay (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Skin (UBERON:0002097) – cutaneous lupus; Tfh/Tph and local immune complexes (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, moysidou2024lymphocyteschangetheir pages 18-20). - CNS (UBERON:0000955) – neuropsychiatric SLE with vasculopathy/microthrombi/inflammation (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4). - Vasculature (UBERON:0001981) – accelerated vascular damage and atherogenesis in SLE inflammatory milieu (moysidou2024lymphocyteschangetheir pages 18-20).
Chemical entities (CHEBI) and biomarkers - DNA/RNA in NETs (CHEBI:16991; CHEBI:33697) – ligands for TLR9/TLR7; NET remnants (e.g., MPO-DNA, CitH3) as activity biomarkers in LN (yuan2024globalresearchtrends pages 10-10). - Cytokines/chemokines: IFN-α, IL-21, CXCL10/CXCL13 as mechanistic biomarkers and stratifiers (wu2025immunecellaberrations pages 29-30). - Complement split products (e.g., C3/C4 consumption) as activity markers linked to immune complex burden (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4, moysidou2024lymphocyteschangetheir pages 18-20).
GO biological processes (disrupted) - Type I interferon signaling pathway (GO:0060337): chronic activation across cell types (wu2025immunecellaberrations pages 29-30). - Toll-like receptor signaling (GO:0002224/GO:0035663): TLR7/9 in B cells/pDCs; MyD88–NF-κB axis (cosgrove2024tolllikereceptor7 pages 160-164, moysidou2024lymphocyteschangetheir pages 18-20). - B cell activation and differentiation (GO:0042113; GO:0030183): IL-21 and BAFF-driven plasma cell formation; ABC expansion (wu2025immunecellaberrations pages 29-30, shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Neutrophil degranulation and NET formation (GO:0043312; GO:0036349): NETs driving IFN/complement loops (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Complement activation, classical pathway (GO:0006958): immune complex–triggered activation; links to LN (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - Apoptotic cell clearance/efferocytosis (GO:0043277): defects expose nuclear antigens (moysidou2024lymphocyteschangetheir pages 18-20).
Cellular components (where processes occur) - Endosome/lysosome (GO:0005768/GO:0005764): TLR7/9 nucleic-acid sensing (cosgrove2024tolllikereceptor7 pages 160-164). - Extracellular region (GO:0005576): NET scaffolds (DNA, histones, granule proteins) and immune complexes (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Plasma membrane/immune synapse (GO:0005886; GO:0001772): Tfh–B cell interactions (ICOS, PD-1) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3).
Disease progression (sequence of events) - Initiation/triggers: genetic predisposition and environmental insults (infections; repeated innate triggers) lower activation thresholds; repeated infections can “break T cell anergy,” driving autoreactive Tfh development (Jul 2025; https://doi.org/10.3390/cells14141080) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Amplification: impaired apoptotic/NET debris clearance and early complement pathway insufficiency promote endogenous nucleic-acid presentation to TLR7/9 (B cells, pDCs) → IFN-α programs and BAFF elevation → ABC and Tfh/Tph expansion → extrafollicular and GC autoantibody responses (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10, wu2025immunecellaberrations pages 29-30, shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Tissue injury: immune complex deposition and complement activation; leukocyte infiltration; NET-associated oxidant injury; organ-specific patterns (glomerulonephritis; cutaneous lesions; neurovascular injury) (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10, justizvaillant2024neuropsychiatricsystemiclupus pages 2-4). - Chronicity and flares: self-sustaining IFN–TLR–B/T feedback loops; persistence of long-lived plasma cells and NET–IFN circuits; fluctuating complement consumption and autoantibody titers (wu2025immunecellaberrations pages 29-30, moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10).
Phenotypic manifestations (HP terms) and mechanistic links - Lupus nephritis (HP:0000127): immune complexes, complement, NETs (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Cutaneous photosensitive rash (HP:0000988/HP:0000684): immune complex vasculitis in skin; Tfh/Tph involvement (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, moysidou2024lymphocyteschangetheir pages 18-20). - Neuropsychiatric features (HP:0100022; HP:0000716): vasculopathy, microthrombi, inflammatory mediators; diagnostic complexity (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4). - Cytopenias (HP:0001873/HP:0001876/HP:0001877): immune-mediated cytopenias consonant with systemic immune complex/complement activation (moysidou2024lymphocyteschangetheir pages 18-20, justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).
Current applications and real-world implementations - IFN-I pathway therapeutics: Anifrolumab (anti–IFNAR1) efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based stratification (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - B-cell–directed strategies: BAFF pathway modulation (belimumab) fits B-cell survival/tolerance failure paradigm summarized here; reviews underscore integrating BAFF/IFN biomarkers with therapeutic selection (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - Cellular therapy: Anti-CD19 CAR-T has induced drug-free remissions in early experiences and is rationalized by B-cell centrality in SLE pathogenesis (Dec 2024; https://doi.org/10.3389/fimmu.2024.1476859) (zhou2024cartcelltherapy pages 4-4). - Biomarkers: NET remnants (e.g., MPO-DNA/CitH3), IFN gene signatures, and chemokines (CXCL10/CXCL13) are candidate activity/response biomarkers tied to the mechanisms above (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350; Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (yuan2024globalresearchtrends pages 10-10, wu2025immunecellaberrations pages 29-30).
Expert opinions and analysis - Reviews integrating immune cell perturbations argue for moving “from single-target blockade to reconstruction of immune network homeostasis,” cautioning against compensatory remodeling and advocating dynamic immunomonitoring (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - Mechanistic syntheses emphasize the TLR7–driven, B cell–intrinsic nature of disease with regulatory inputs from TLR9 and redox signaling (NOX2), suggesting strategies that antagonize TLR7 while preserving/leveraging TLR9’s counter-regulation (2024 synthesis) (cosgrove2024tolllikereceptor7 pages 160-164).
Relevant statistics and data (recent) - NETs: impaired degradation associates with LN; mechanistically, LL37/HNP–DNA complexes resist nucleases and activate pDC TLR9 to induce IFN-α (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (yuan2024globalresearchtrends pages 10-10). - IFN biomarker–therapy link: high IFN gene signature correlates with better response to anifrolumab (precise wording per review figure/text) (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - B cell–intrinsic TLR7: genetic deletion of Tlr7 in B cells rescues severe disease in specific lupus-prone backgrounds; NOX2 deficiency augments TLR7–NF-κB signaling (experimental findings synthesized in 2024 work) (cosgrove2024tolllikereceptor7 pages 160-164). - NPSLE: clinicopathologic heterogeneity and absence of a single confirmatory laboratory test underscore the need for multimodal biomarkers (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).
Gene/protein annotations and ontology mappings - HGNC: TLR7 (HGNC:15631); MYD88 (HGNC:7562); CYBB/NOX2 (HGNC:2553); TNFSF13B/BAFF (HGNC:11929); IL21 (HGNC:6008); IFNA1 family (HGNC:5399). - GO processes: GO:0060337 (type I IFN signaling); GO:0002224/GO:0035663 (TLR signaling); GO:0030183 (B cell differentiation); GO:0036349 (NET formation); GO:0006958 (complement activation, classical pathway); GO:0043277 (apoptotic cell clearance). - CL: pDCs (CL:0000784); B cells (CL:0000236) including ABCs; Tfh (CL:0002038); neutrophils (CL:0000096); Tph-like cells. - UBERON: kidney (UBERON:0002113), glomerulus (UBERON:0000071); skin (UBERON:0002097); brain (UBERON:0000955); vasculature (UBERON:0001981). - CHEBI: nucleic acids (DNA, CHEBI:16991; RNA, CHEBI:33697); chemokines/cytokines as applicable. - HP: lupus nephritis (HP:0000127); malar/photosensitive rash (HP:0000988); neuropsychiatric features (HP:0100022); leukopenia/thrombocytopenia/anemia (HP:0001882/HP:0001873/HP:0001876).
Evidence items (PMIDs/DOIs/URLs and dates) - Moysidou E, et al. Lymphocytes change their phenotype and function in SLE and LN. Int J Mol Sci. Oct 2024. URL: https://doi.org/10.3390/ijms252010905 (moysidou2024lymphocyteschangetheir pages 18-20). - Yuan Z, et al. Global precision-targeted therapies in SLE; NETs–IFN loop and biomarkers. Heliyon. Jul 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e33350 (yuan2024globalresearchtrends pages 10-10). - Wu YX, et al. Immune cell aberrations and precision management in SLE; IFN signature–anifrolumab link. Cell Mol Biol Lett. Jun 2025. URL: https://doi.org/10.1186/s11658-025-00749-z (wu2025immunecellaberrations pages 29-30). - Zhou J, et al. CAR T-cell therapy for SLE: current status and perspectives. Front Immunol. Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1476859 (zhou2024cartcelltherapy pages 4-4). - Cosgrove HA. TLR7 in SLE: B cell–intrinsic roles and NOX2 regulation. 2024 research synthesis (cosgrove2024tolllikereceptor7 pages 160-164). - Shiozawa S. Tfh and infection-triggered models; ICOS/IL-21 involvement. Cells. Jul 2025. URL: https://doi.org/10.3390/cells14141080 (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Justiz-Vaillant AA, et al. NPSLE: molecules, features, treatment; diagnostic caveats. Molecules. Feb 2024. URL: https://doi.org/10.3390/molecules29040747 (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).
Limitations and open questions - While IFN-I and TLR7/9 biology are strongly implicated, the relative contributions of endosomal sensing versus cytosolic nucleic-acid–sensing (e.g., cGAS–STING) pathways in human SLE subsets remain active areas. Mechanism-guided stratification (IFN gene signatures; NET biomarkers) shows promise but requires prospective standardization (wu2025immunecellaberrations pages 29-30, yuan2024globalresearchtrends pages 10-10). - The protective–pathogenic duality of TLR9 and context-dependent roles of redox signaling (NOX2) suggest that pathway-selective modulation, not blanket inhibition, may be necessary (cosgrove2024tolllikereceptor7 pages 160-164).
Citations (support for major claims) - Core mechanisms (IFN axis, TLR7/9, impaired clearance, NETosis/complement, B/T help): (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10, cosgrove2024tolllikereceptor7 pages 160-164, shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - IFN signature and therapy response (anifrolumab): (wu2025immunecellaberrations pages 29-30). - NETs as mechanistic drivers and LN biomarkers: (yuan2024globalresearchtrends pages 10-10). - CAR-T and B-cell centrality: (zhou2024cartcelltherapy pages 4-4). - NPSLE pathogenesis complexity and diagnostics: (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).
References
(moysidou2024lymphocyteschangetheir pages 18-20): Eleni Moysidou, Michalis Christodoulou, Georgios Lioulios, Stamatia Stai, Theodoros Karamitsos, Theodoros Dimitroulas, Asimina Fylaktou, and Maria Stangou. Lymphocytes change their phenotype and function in systemic lupus erythematosus and lupus nephritis. International Journal of Molecular Sciences, 25:10905, Oct 2024. URL: https://doi.org/10.3390/ijms252010905, doi:10.3390/ijms252010905. This article has 10 citations and is from a poor quality or predatory journal.
(yuan2024globalresearchtrends pages 10-10): Zengze Yuan, Weiqing Zhang, Zhaokai Jin, Yihan Wang, Zhiting Lin, Zhimin Xie, and Xinchang Wang. Global research trends in precision-targeted therapies for systemic lupus erythematosus (2003–2023): a bibliographic study. Heliyon, 10:e33350, Jul 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e33350, doi:10.1016/j.heliyon.2024.e33350. This article has 2 citations and is from a peer-reviewed journal.
(wu2025immunecellaberrations pages 29-30): YuXian Wu, Wangzheqi Zhang, Yan Liao, Ting Sun, Yang Liu, and Yaoyang Liu. Immune cell aberrations in systemic lupus erythematosus: navigating the targeted therapies toward precision management. Cellular & Molecular Biology Letters, Jun 2025. URL: https://doi.org/10.1186/s11658-025-00749-z, doi:10.1186/s11658-025-00749-z. This article has 6 citations and is from a peer-reviewed journal.
(cosgrove2024tolllikereceptor7 pages 160-164): HA Cosgrove. Toll-like receptor 7 in systemic lupus erythematosus: characterization of cell-intrinsic roles and regulation by nadph oxidase. Unknown journal, 2024.
(shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3): Shunichi Shiozawa. Pathogenesis of autoimmunity/systemic lupus erythematosus (sle). Cells, 14:1080, Jul 2025. URL: https://doi.org/10.3390/cells14141080, doi:10.3390/cells14141080. This article has 1 citations and is from a poor quality or predatory journal.
(justizvaillant2024neuropsychiatricsystemiclupus pages 2-4): Angel A. Justiz-Vaillant, Darren Gopaul, Sachin Soodeen, Rodolfo Arozarena-Fundora, Odette Arozarena Barbosa, Chandrashehkar Unakal, Reinand Thompson, Bijay Pandit, Srikanth Umakanthan, and Patrick E. Akpaka. Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment. Molecules, 29:747, Feb 2024. URL: https://doi.org/10.3390/molecules29040747, doi:10.3390/molecules29040747. This article has 58 citations and is from a poor quality or predatory journal.
(zhou2024cartcelltherapy pages 4-4): Jincai Zhou, Bixia Lei, Feifei Shi, Xinran Luo, Kai Wu, Yanhong Xu, Yuting Zhang, Rongjiao Liu, Huajing Wang, Joy Zhou, and Xiaowen He. Car t-cell therapy for systemic lupus erythematosus: current status and future perspectives. Frontiers in Immunology, Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1476859, doi:10.3389/fimmu.2024.1476859. This article has 22 citations and is from a peer-reviewed journal.
name: Systemic Lupus Erythematosus
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-03T20:00:00Z'
description: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific
category: Complex
parents:
- Autoimmune Disease
has_subtypes:
- name: Discoid Lupus Erythematosus
description: Primarily affects the skin.
evidence:
- reference: PMID:30988213
reference_title: "[Systemic Lupus Erythematosus]."
supports: SUPPORT
snippet: The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE.
explanation: Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.
- reference: PMID:7763220
reference_title: "Discoid lupus erythematosus."
supports: SUPPORT
snippet: Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement.
explanation: This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.
- reference: PMID:28941498
reference_title: "Not Just Skin Deep: Systemic Disease Involvement in Patients With Cutaneous Lupus."
supports: SUPPORT
snippet: Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types.
explanation: This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.
- name: Neonatal Lupus
description: Affects infants, caused by transplacental transfer of maternal autoantibodies.
evidence:
- reference: PMID:9287379
reference_title: "Neonatal lupus erythematosus."
supports: SUPPORT
snippet: neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies.
explanation: This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.
- reference: PMID:24763535
reference_title: "The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes."
supports: SUPPORT
snippet: Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB).
explanation: The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.
- reference: PMID:15744116
reference_title: "[Neonatal lupus syndrome]."
supports: SUPPORT
snippet: Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta.
explanation: This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.
- reference: PMID:3521977
reference_title: "Lupus erythematosus in childhood."
supports: SUPPORT
snippet: 'Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus...'
explanation: This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors.
- reference: PMID:22832822
reference_title: "Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease."
supports: PARTIAL
snippet: Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy.
explanation: This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn't explicitly say it's a systemic lupus erythematosus subtype.
- name: Drug-Induced Lupus
description: Caused by certain medications and usually reversible.
evidence:
- reference: PMID:1356074
reference_title: "Medication-induced systemic lupus erythematosus."
supports: SUPPORT
snippet: The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE.
explanation: This indicates that there is a distinct subtype of SLE induced by medications.
- reference: PMID:23164669
reference_title: "Drug-induced lupus erythematosus."
supports: SUPPORT
snippet: Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal.
explanation: This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.
- reference: PMID:1751313
reference_title: "Drug-related lupus."
supports: SUPPORT
snippet: All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself.
explanation: This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.
- reference: PMID:25037258
reference_title: "Severe drug-induced dermatoses."
supports: SUPPORT
snippet: This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus...
explanation: This article covers drug-induced lupus, affirming the existence of this subtype linked to medications.
pathophysiology:
- name: Formation of Immune Complexes
biological_processes:
- preferred_term: Immunoglobulin production
term:
id: GO:0002377
label: immunoglobulin production
- preferred_term: Complement activation, classical pathway
term:
id: GO:0006958
label: complement activation, classical pathway
- preferred_term: B cell mediated immunity
term:
id: GO:0019724
label: B cell mediated immunity
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: plasma cell
term:
id: CL:0000786
label: plasma cell
- preferred_term: macrophage
term:
id: CL:0000235
label: macrophage
evidence:
- reference: PMID:27709413
reference_title: "Immune Cell Metabolism in Systemic Lupus Erythematosus."
supports: PARTIAL
snippet: Here, we review what is known on the altered metabolic patterns of CD4(+) T cells, B cells, and myeloid cells in lupus patients and lupus-prone mice and how they contribute to lupus pathogenesis.
explanation: The reference discusses the altered metabolic patterns of B cells, CD4(+) T cells, and myeloid cells (which include macrophages) and their contribution to lupus, which indirectly supports the involvement of these cell types in lupus mechanisms, but it does not specifically address immune complex formation directly.
- reference: PMID:29925508
reference_title: "TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus."
supports: PARTIAL
snippet: TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus.
explanation: This reference demonstrates the role of specific plasma cells in the development of lupus nephritis, implying their role in immune complex-related pathology, but does not detail the direct involvement of B cells or macrophages in immune complex formation.
- reference: PMID:34402453
reference_title: "Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus."
supports: PARTIAL
snippet: B-lymphocytes are crucial in the pathogenesis of systemic lupus erythematosus (SLE), including autoantibody production, antigen presentation, co-stimulation, and cytokine secretion.
explanation: The reference highlights the crucial role of B cells in the pathogenesis of SLE through mechanisms such as autoantibody production, which is critical for immune complex formation. However, it does not explicitly discuss the role of plasma cells or macrophages in the context given.
- reference: PMID:22999705
reference_title: "Complement, interferon and lupus."
supports: PARTIAL
snippet: C1q opsonized apoptotic cells also exert an immunosuppressive effect through cytokine regulation and the stimulation of additional opsonins by macrophages.
explanation: This suggests that macrophages have a role in immune complex-mediated processes through cytokine regulation and opsonin stimulation, contributing to the immune system’s activity in lupus but does not detail the involvement of B cells or plasma cells in immune complex formation.
- name: Glomerular Immune Complex Deposition
description: >
Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies
lodge in kidney glomeruli, activating complement and recruiting inflammatory
cells.
locations:
- preferred_term: Kidney
term:
id: UBERON:0002113
label: kidney
biological_processes:
- preferred_term: complement activation
term:
id: GO:0006956
label: complement activation
downstream:
- target: Lupus Nephritis
description: Immune complex deposition in glomeruli triggers local inflammation and tissue damage.
evidence:
- reference: PMID:33841392
reference_title: "Deposition of Immune Complexes in Gingival Tissues in the Presence of Periodontitis and Systemic Lupus Erythematosus."
supports: SUPPORT
snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges. Deposition of immune complexes in kidneys glomeruli are associated with lupus nephritis, determining SLE diagnosis.
explanation: The literature supports the deposition of immune complexes in kidney glomeruli but does not cover skeletal joints, skin, heart, or lung in this context.
- reference: PMID:30009962
reference_title: "Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers."
supports: SUPPORT
snippet: LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins.
explanation: This confirms immune complex deposition in kidneys.
- name: Cutaneous Immune Complex Deposition
description: >
Immune complexes deposit at the dermal-epidermal junction and in vessel
walls of the skin, leading to cutaneous manifestations of lupus.
locations:
- preferred_term: Skin
term:
id: UBERON:0002097
label: skin of body
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:35872103
reference_title: "Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target."
supports: SUPPORT
snippet: The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS).
explanation: This paper directly establishes that autoantibodies form immune complexes which cause inflammatory damage to multiple organs in SLE.
- reference: PMID:16572034
reference_title: "The pathogenesis of systemic lupus erythematosus."
supports: SUPPORT
snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
explanation: The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.
- name: Synovial Immune Complex Deposition
description: >
Immune complexes accumulate in synovial fluid and tissue of joints,
activating complement and triggering inflammatory arthritis.
locations:
- preferred_term: Skeletal Joint
term:
id: UBERON:0000982
label: skeletal joint
biological_processes:
- preferred_term: complement activation
term:
id: GO:0006956
label: complement activation
evidence:
- reference: PMID:16572034
reference_title: "The pathogenesis of systemic lupus erythematosus."
supports: SUPPORT
snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
explanation: The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.
- reference: PMID:2860699
reference_title: "Cardiovascular manifestations of systemic lupus erythematosus: current perspective."
supports: NO_EVIDENCE
snippet: Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis.
explanation: This confirms immune complex deposition in the heart.
- reference: PMID:28900675
reference_title: "Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus."
supports: NO_EVIDENCE
snippet: Recent studies demonstrated an increased incidence of osteoporosis and peripheral and vertebral fractures in patients with SLE
explanation: This reference does not mention the deposition of immune complexes in skeletal joints.
- reference: PMID:158982
reference_title: "Immune complex injury of the lung."
supports: NO_EVIDENCE
snippet: Abundant evidence currently exists to suggest that immune complexes play an important role in inflammatory diseases of the lung. ... systemic lupus erythematosus have been shown to be associated with the presence of immune complexes both in lung and in the serum.
explanation: This confirms immune complex deposition in the lung.
- name: Inflammation And Tissue Damage
evidence:
- reference: PMID:22192660
reference_title: "Mechanisms of tissue injury in lupus nephritis."
supports: SUPPORT
snippet: Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage.
explanation: The article describes inflammation and immune complex deposition as mechanisms leading to tissue damage in SLE.
- reference: PMID:36555640
reference_title: "Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies."
supports: SUPPORT
snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
explanation: The literature explains that inflammation and tissue damage are core mechanisms in the pathology of SLE due to immune system disturbances.
- reference: PMID:28623084
reference_title: "Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective."
supports: SUPPORT
snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. A complex interaction of genetics, environment, and hormones leads to immune dysregulation and breakdown of tolerance to self-antigens, resulting in autoantibody production, inflammation, and destruction of end-organs.
explanation: This article outlines inflammation as part of the immune dysregulation in SLE, leading to tissue damage in multiple organs.
- reference: PMID:33841392
reference_title: "Deposition of Immune Complexes in Gingival Tissues in the Presence of Periodontitis and Systemic Lupus Erythematosus."
supports: SUPPORT
snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges.
explanation: The study identifies widespread inflammation and tissue damage as defining characteristics of SLE.
- reference: PMID:37712757
reference_title: "Biomarkers for systemic lupus erythematosus - a focus on organ damage."
supports: SUPPORT
snippet: In the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment.
explanation: The review supports that inflammation and tissue damage are significant mechanisms in SLE affecting organs such as the skin, kidneys, and nervous system.
- name: Chronic Inflammation
evidence:
- reference: PMID:16572034
reference_title: "The pathogenesis of systemic lupus erythematosus."
supports: SUPPORT
snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues...
explanation: The abstract confirms that inflammation is a key aspect of systemic lupus erythematosus pathogenesis.
- reference: PMID:26330673
reference_title: "Identification of Candidate Predictors of Lupus Flare."
supports: SUPPORT
snippet: Systemic lupus erythematosus, the prototype systemic autoimmune disease, is characterized by extensive self-reactivity, inflammation, and organ system damage.
explanation: The abstract clearly mentions inflammation as a characteristic feature of SLE.
- reference: PMID:32237942
reference_title: "Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations."
supports: SUPPORT
snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ.
explanation: The literature describes SLE as a chronic autoimmune disease affecting various organs, implying sustained inflammation over time.
- reference: PMID:24992143
reference_title: "The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?"
supports: SUPPORT
snippet: Recent evidence suggests that the inflammasome machinery is dysregulated in SLE, plays an important role in promotion of organ damage, and may mediate cross-talk between environmental triggers and the development of lupus.
explanation: The abstract discusses the role of inflammasome and inflammation in organ damage associated with SLE, supporting the chronic inflammation mechanism.
- reference: PMID:36555640
reference_title: "Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies."
supports: SUPPORT
snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
explanation: The literature describes inflammation and tissue damage due to immune complexes, which supports chronic inflammation as a mechanism of SLE.
- name: Flare-Ups
description: The symptoms of lupus can worsen suddenly in episodes known as flares, which can be triggered by factors like stress, sunlight, and infections.
evidence:
- reference: PMID:26951252
reference_title: "What Causes Lupus Flares?"
supports: SUPPORT
snippet: These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms.
explanation: This reference mentions the potential triggers for lupus flares, which include UV light (sunlight) and infections.
- reference: PMID:26494589
reference_title: "Systemic lupus erythematosus flare triggered by a spider bite."
supports: SUPPORT
snippet: Some triggers for these exacerbations have been identified, including infections, vaccines, pregnancy, environmental factors such as weather, stress and drugs.
explanation: This reference specifically states that stress and infections can trigger lupus flares.
- reference: PMID:22385883
reference_title: "Seasonal variations of systemic lupus erythematosus flares in southern France."
supports: SUPPORT
snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
explanation: This reference confirms that sunlight exposure can trigger lupus flares.
- reference: PMID:30488801
reference_title: "Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations."
supports: NO_EVIDENCE
snippet: The cutaneous manifestations that were present included malar rash 37.69%, photosensitivity 35.10%, discoid lupus 17.63%, and hair loss 39.29%.
explanation: This reference discusses photosensitivity (sunlight) as a significant factor, aligning with the statement's mention of sunlight as a trigger.
- name: Type I Interferon Pathway Activation
description: Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.
cell_types:
- preferred_term: plasmacytoid dendritic cell
term:
id: CL:0000784
label: plasmacytoid dendritic cell
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: type I interferon signaling pathway
term:
id: GO:0060337
label: type I interferon-mediated signaling pathway
evidence:
- reference: PMID:24834763
reference_title: "Type I interferon signature in systemic lupus erythematosus."
supports: SUPPORT
snippet: An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE.
explanation: This review describes the type I interferon gene signature in SLE, supporting chronic activation of the type I interferon pathway.
- name: TLR7/TLR9-Mediated Nucleic Acid Sensing
description: B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: plasmacytoid dendritic cell
term:
id: CL:0000784
label: plasmacytoid dendritic cell
biological_processes:
- preferred_term: toll-like receptor signaling pathway
term:
id: GO:0002224
label: toll-like receptor signaling pathway
- preferred_term: toll-like receptor 7 signaling pathway
term:
id: GO:0034154
label: toll-like receptor 7 signaling pathway
- preferred_term: toll-like receptor 9 signaling pathway
term:
id: GO:0034162
label: toll-like receptor 9 signaling pathway
- name: NETosis and Neutrophil Extracellular Trap Formation
description: Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.
cell_types:
- preferred_term: neutrophil
term:
id: CL:0000775
label: neutrophil
biological_processes:
- preferred_term: neutrophil degranulation
term:
id: GO:0043312
label: neutrophil degranulation
- preferred_term: neutrophil extracellular trap formation
term:
id: GO:0140645
label: neutrophil extracellular trap formation
- name: Age-Associated B Cell Expansion
description: Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: B cell activation
term:
id: GO:0042113
label: B cell activation
- preferred_term: B cell differentiation
term:
id: GO:0030183
label: B cell differentiation
- name: T Follicular Helper Cell Dysregulation
description: T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.
cell_types:
- preferred_term: T follicular helper cell
term:
id: CL:0002038
label: T follicular helper cell
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: T cell activation
term:
id: GO:0042110
label: T cell activation
- preferred_term: germinal center formation
term:
id: GO:0002467
label: germinal center formation
- name: Impaired Apoptotic Cell Clearance
description: Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.
biological_processes:
- preferred_term: apoptotic cell clearance
term:
id: GO:0043277
label: apoptotic cell clearance
- preferred_term: efferocytosis
term:
id: GO:0043277
label: apoptotic cell clearance
- name: Complement Pathway Dysregulation
description: Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.
biological_processes:
- preferred_term: complement activation, classical pathway
term:
id: GO:0006958
label: complement activation, classical pathway
locations:
- preferred_term: Kidney
term:
id: UBERON:0002113
label: kidney
- preferred_term: Glomerulus
term:
id: UBERON:0000074
label: renal glomerulus
- name: Epigenetic Dysregulation and T Cell Metabolic Reprogramming
description: >
Aberrant DNA methylation, histone modifications, and metabolic reprogramming
in T cells contribute to lupus pathogenesis. Hypomethylation of immune gene
loci activates autoreactive T cells, while metabolic shifts including altered
mTOR signaling and glutaminolysis support inflammatory T cell programs.
cell_types:
- preferred_term: CD4-positive helper T cell
term:
id: CL:0000492
label: CD4-positive helper T cell
biological_processes:
- preferred_term: Epigenetic Regulation of Gene Expression
term:
id: GO:0040029
label: epigenetic regulation of gene expression
- preferred_term: T Cell Differentiation
term:
id: GO:0030217
label: T cell differentiation
downstream:
- target: Autoantibody Production
description: Dysregulated T cell programs promote autoreactive B cell help and autoantibody production
notes: >
Cluster 100 (ATF4, GLS, CBLB) from Zhu/Dann Perturb-seq shows OR=3.7 for SLE, the
strongest signal for this metabolic/stress response regulatory program. DNA methylation
changes are well-established in lupus T cells.
phenotypes:
- category: Cutaneoous
name: Malar Rash
frequency: FREQUENT
diagnostic: true
evidence:
- reference: PMID:23846232
reference_title: "Systemic lupus erythematosus in the multiethnic Malaysian population: disease expression and ethnic differences revisited."
supports: PARTIAL
snippet: The most common clinical manifestations were malar rash (61.3%)...
explanation: The literature supports that malar rash is a common manifestation of systemic lupus erythematosus (SLE), but it does not specifically categorize it under 'Cutaneous'.
- reference: PMID:16966017
reference_title: "Lupus erythematosus: systemic and cutaneous manifestations."
supports: PARTIAL
snippet: 'There are 3 forms of cutaneous lupus: chronic cutaneous (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus.'
explanation: This reference discusses cutaneous forms of lupus but does not specifically mention malar rash as one of these types.
- reference: PMID:17711886
reference_title: "Making the diagnosis of systemic lupus erythematosus in children and adolescents."
supports: PARTIAL
snippet: The common symptoms of SLE in children and adolescents include... rash...
explanation: This reference indicates that rash, which can include malar rash, is common in SLE, but it does not specifically categorize malar rash as 'Cutaneous'.
phenotype_term:
preferred_term: Malar Rash
term:
id: HP:0025300
label: Malar rash
- category: Cutaneoous
name: Photosensitivity
frequency: FREQUENT
evidence:
- reference: PMID:15379880
reference_title: "Photosensitivity in lupus erythematosus."
supports: SUPPORT
snippet: Photosensitivity is one the most common manifestations of lupus erythematosus.
explanation: The literature directly mentions that photosensitivity is a common manifestation in lupus erythematosus, supporting the statement that it is a frequent phenotype.
- reference: PMID:31909888
reference_title: "Using Clinical Characteristics and Patient-Reported Outcome Measures to Categorize Systemic Lupus Erythematosus Subtypes."
supports: PARTIAL
snippet: Fatigue, widespread pain, sleep dysfunction, and mood disorders are common symptoms in SLE.
explanation: While this reference mentions common symptoms of SLE, it does not specifically address photosensitivity.
- reference: PMID:30988213
reference_title: "[Systemic Lupus Erythematosus]."
supports: PARTIAL
snippet: The cutaneous manifestations of lupus erythematosus (LE) include LE-specific and LE-nonspecific skin lesions.
explanation: The reference discusses cutaneous manifestations of LE but does not specifically highlight photosensitivity.
- reference: PMID:31575058
reference_title: "Update on the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond."
supports: PARTIAL
snippet: The development of SLE is attributed to the breach of immunological tolerance and the interaction between SLE-susceptibility genes and various environmental factors.
explanation: While the reference discusses factors contributing to the development of SLE, it does not explicitly address photosensitivity.
- reference: PMID:23846232
reference_title: "Systemic lupus erythematosus in the multiethnic Malaysian population: disease expression and ethnic differences revisited."
supports: PARTIAL
snippet: The most common clinical manifestations were malar rash (61.3%), arthritis (52.3%), haematological disease (51.6%), oral ulcers (51%) and renal disease (40.6%).
explanation: Photosensitivity is not specifically mentioned among the most common clinical manifestations in this study.
- reference: PMID:29087262
reference_title: "Systemic lupus erythematosus with and without a family history: a meta-analysis."
supports: PARTIAL
snippet: Analysis revealed that photosensitivity, nephritis and thrombocytopenia were negatively associated with familial SLE.
explanation: This reference suggests that photosensitivity is common in non-familial SLE, indirectly supporting the statement regarding its frequency.
phenotype_term:
preferred_term: Photosensitivity
term:
id: HP:0000992
label: Cutaneous photosensitivity
- category: Musculoskeletal
name: Arthritis
frequency: FREQUENT
evidence:
- reference: PMID:19591780
reference_title: "Lupus arthritis."
supports: SUPPORT
snippet: Arthritis in systemic lupus erythematosus (SLE) is one of the most common disease manifestations. Nearly all joints can be affected by SLE, but hand and knee involvement are the most typical.
explanation: This reference explicitly states that arthritis is one of the most common disease manifestations in patients with SLE.
- reference: PMID:27742023
reference_title: "Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis."
supports: PARTIAL
snippet: The precise nature of the disorder can be obscure and different disorders can present with similar symptoms, such as joint pain.
explanation: The statement mentions joint pain, which is associated with arthritis and suggests that musculoskeletal symptoms are common in SLE.
- reference: PMID:19013374
reference_title: "Deforming arthropathy in systemic lupus erythematosus."
supports: SUPPORT
snippet: Systemic lupus erythematosus is an autoimmune and inflammatory disease characterized by a variety of symptoms, including arthropathy. The clinical presentation of joint involvement varies, ranging from arthralgia without erosions or deformity to an erosive arthropathy and severe functional disability.
explanation: This reference elaborates on the different forms of joint involvement in SLE, including arthropathy, which reinforces the statement that arthritis is a common musculoskeletal phenotype in SLE.
- reference: PMID:32956154
reference_title: "Frequency of Polyautoimmunity in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus."
supports: PARTIAL
snippet: Polyautoimmunity was recorded in 15 patients with RA (13.8%), 43 with SLE (41%), and 2 controls (2.2%). ... In SLE, joint damage (OR, 2.282; p = 0.038) and anti-RNP antibodies (OR, 5.095; p = 0.028) were risk factors for polyautoimmunity...
explanation: This reference indicates a significant association between SLE and joint damage, further supporting the statement.
phenotype_term:
preferred_term: Arthritis
term:
id: HP:0001369
label: Arthritis
- category: Renal
name: Kidney Involvement
evidence:
- reference: PMID:36251502
reference_title: "Prevalence and Patterns of Renal Involvement Among Patients With Systemic Lupus Erythematous at a Tertiary Center."
supports: SUPPORT
snippet: Among 365 patients with SLE, 36% had LN.
explanation: The study indicates that a significant portion of patients with Systemic Lupus Erythematosus (SLE) exhibit kidney involvement in the form of lupus nephritis (LN).
- reference: PMID:330103
reference_title: "Kidney in lupus erythematosus."
supports: SUPPORT
snippet: 'The pathologic abnormalities present in patients with SLE have been classified as follows: minimal lupus nephritis, mild (focal) proliferative lupus nephritis, severe (diffuse) proliferative lupus nephritis, and membranous lupus nephritis.'
explanation: The classification of pathologic abnormalities in SLE patients includes various forms of lupus nephritis, which confirms kidney involvement.
- reference: PMID:30454753
reference_title: "Lupus Nephritis."
supports: SUPPORT
snippet: Patients with early onset SLE tend to have a greater genetic component to their disease cause, more multisystemic involvement, and a more severe disease course, which includes greater risks for developing nephritis and end-stage kidney disease.
explanation: This study highlights that childhood-onset SLE has a high risk of developing nephritis, underlining kidney involvement as a significant phenotype.
- category: Hematologic
name: Kidney Involvement
evidence:
- reference: PMID:32725543
reference_title: "Kidney outcomes for children with lupus nephritis."
supports: NO_EVIDENCE
snippet: Kidney involvement occurs in over 50% of children and treatment decisions are guided by the histological classification.
explanation: The study discusses kidney involvement in pediatric SLE but does not categorize it as "Hematologic phenotype".
- reference: PMID:22312827
reference_title: "[Systemic lupus erythematosus]."
supports: NO_EVIDENCE
snippet: Systemic lupus erythematosus (SLE) is a chronic syndrome with unknown etiology and polymorphic clinical picture... Severe SLE involves glomerulonephritis, complications in the central nervous system, cardiac and pulmonary complications and major changes in the blood.
explanation: The literature describes both hematologic changes and kidney involvement separately but does not categorically combine them into a single phenotype.
- reference: PMID:14717922
reference_title: "The classification of glomerulonephritis in systemic lupus erythematosus revisited."
supports: NO_EVIDENCE
snippet: The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis... The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions.
explanation: This paper details the classification of lupus nephritis but does not mention it as a hematologic phenotype.
- reference: PMID:36251502
reference_title: "Prevalence and Patterns of Renal Involvement Among Patients With Systemic Lupus Erythematous at a Tertiary Center."
supports: NO_EVIDENCE
snippet: 'CONCLUSION: This study aids in the recognition of the demographic, clinical, laboratory features, and the histological patterns of LN patients in Saudi Arabia, that probably has a role in the development and disease progression.'
explanation: This study focuses on the prevalence and patterns of lupus nephritis but does not treat it as a hematologic phenotype.
- category: Renal
frequency: FREQUENT
name: Lupus Nephritis
notes: Inflammation of the kidneys, can lead to renal failure
evidence:
- reference: PMID:16530602
reference_title: "Lupus nephritis."
supports: SUPPORT
snippet: Lupus nephritis is one of the more serious manifestations of the systemic autoimmune disease, systemic lupus erythematosus, and is associated with considerable morbidity and even mortality.
explanation: The reference confirms that lupus nephritis is a serious and frequent manifestation of systemic lupus erythematosus (SLE).
- reference: PMID:32295853
reference_title: "Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis."
supports: SUPPORT
snippet: The frequency of endstage renal disease (ESRD) from systemic lupus erythematosus (SLE) in the United States has not improved over the last few decades in large population datasets.
explanation: The reference indicates the prevalence of renal complications, including end-stage renal disease, in SLE patients.
- reference: PMID:35775489
reference_title: "Lymphocytes in the neighborhood: good or bad for the kidney?"
supports: SUPPORT
snippet: Lupus nephritis (LN) is common in people with systemic lupus erythematosus (SLE) and advances, almost invariably, to end-stage renal disease (ESRD).
explanation: The reference supports that lupus nephritis is a common and serious renal manifestation in SLE, often leading to ESRD.
- reference: PMID:22192934
reference_title: "[Renal involvement in systemic lupus erythematosus]."
supports: SUPPORT
snippet: Renal involvement is frequent (20 to 50% of cases) during the course of systemic lupus erythematosus (SLE).
explanation: The reference states that renal involvement, including lupus nephritis, is frequent in SLE patients.
phenotype_term:
preferred_term: Lupus Nephritis
term:
id: HP:0033726
label: Lupus nephritis
- category: Hematologic
frequency: FREQUENT
name: Leukopenia
notes: Low white blood cell count
evidence:
- reference: PMID:26170228
reference_title: "Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review."
supports: SUPPORT
snippet: The prevalence of leukopenia is reported in 22-41.8% of cases.
explanation: The study reports that leukopenia is prevalent in 22-41.8% of SLE cases, indicating that leukopenia is a frequent hematologic abnormality in SLE patients.
- reference: PMID:27590999
reference_title: "Prognostic significance of platelet count in SLE patients."
supports: PARTIAL
snippet: TCP was the most prevalent hematological abnormality evident in 15%, more than leucopenia (14%) and anemia (2%).
explanation: Although thrombocytopenia was the most prevalent, leukopenia was still present in 14% of the cases, supporting the statement that leukopenia is a frequent hematologic abnormality in SLE patients.
- reference: PMID:8130682
reference_title: "Haematological manifestations of systemic lupus erythematosus."
supports: PARTIAL
snippet: The increased risk of infection in patients with SLE is due in part to changes in the white blood cells though treatments do not yet aim to modify these.
explanation: The study mentions changes in white blood cells, including leukopenia, as a common hematologic manifestation in SLE patients.
- reference: PMID:15580984
reference_title: "Review of ACR hematologic criteria in systemic lupus erythematosus."
supports: SUPPORT
snippet: 'In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis); 2) leukopenia (<4000/microL on two or more occasions)... is now considered as a single hematologic disorder.'
explanation: The ACR criteria include leukopenia as a significant hematologic disorder in the diagnosis of SLE, supporting its frequent occurrence.
phenotype_term:
preferred_term: Leukopenia
term:
id: HP:0001882
label: Decreased total leukocyte count
- category: Hematologic
frequency: FREQUENT
name: Thrombocytopenia
notes: Low platelet count
evidence:
- reference: PMID:32896257
reference_title: "Prevalence and outcome of thrombocytopenia in systemic lupus erythematous: single-centre cohort analysis."
supports: PARTIAL
snippet: Thrombocytopenia was classified as mild (100-149x109/L), moderate (31-99x109/L) or severe (</=30x109/L platelets).
explanation: The study shows that thrombocytopenia is a common occurrence in SLE patients, with a significant portion experiencing various degrees of thrombocytopenia.
- reference: PMID:12481500
reference_title: "[Hematological abnormalities in patients with systemic lupus erythematosus]."
supports: SUPPORT
snippet: Thrombocytopenia is common, autoimmune and associated with a decreased survival.
explanation: This reference confirms that thrombocytopenia is a common hematologic abnormality in SLE patients.
- reference: PMID:15580984
reference_title: "Review of ACR hematologic criteria in systemic lupus erythematosus."
supports: SUPPORT
snippet: Thrombocytopenia (< 100,000/microL in the absence of offending drugs) is now considered as a single hematologic disorder.
explanation: This review highlights thrombocytopenia as a significant hematologic criterion for diagnosing SLE.
phenotype_term:
preferred_term: Thrombocytopenia
term:
id: HP:0001873
label: Thrombocytopenia
- category: Hematologic
frequency: OCCASIONAL
name: Hemolytic Anemia
notes: Destruction of red blood cells
evidence:
- reference: PMID:12481500
reference_title: "[Hematological abnormalities in patients with systemic lupus erythematosus]."
supports: NO_EVIDENCE
snippet: 'Anaemia is the most common hematological abnormality in SLE, it is multifactorial. The most common form of anaemia is that of chronic disease, and it is relate with inflammatory cytokines. Other tips of anaemia are: iron deficiency anaemia, autoimmune haemolytic anaemia, pure red cell aplasia.'
explanation: The abstract mentions that autoimmune hemolytic anemia is one of the types of anemia in SLE but does not provide information about its frequency.
- reference: PMID:36469203
reference_title: "Circulating Levels of Hypoxia-regulating MicroRNAs in Systemic Lupus Erythematosus Patients with Hemolytic Anemia."
supports: PARTIAL
snippet: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that would potentiate many pathological complications, including hemolytic anemia.
explanation: This reference confirms that hemolytic anemia is one of the complications of SLE.
- reference: PMID:15580984
reference_title: "Review of ACR hematologic criteria in systemic lupus erythematosus."
supports: PARTIAL
snippet: 'In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis)... is now considered as a single hematologic disorder.'
explanation: The ACR criteria for diagnosing SLE includes hemolytic anemia as one of the hematologic disorders.
- reference: PMID:30631001
reference_title: "Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus."
supports: PARTIAL
snippet: One month prior, she had been diagnosed with Evans syndrome (haemolytic anemia with positive Coombs test and thrombocytopenia)... Further examination revealed positive for ANA, anti-SSA, and diagnosis of SLE was established.
explanation: This case study describes a patient with hemolytic anemia who was diagnosed with SLE.
phenotype_term:
preferred_term: Hemolytic Anemia
term:
id: HP:0001878
label: Hemolytic anemia
- category: Cardiac
frequency: OCCASIONAL
name: Pericarditis
notes: Inflammation of the pericardium (lining around the heart)
evidence:
- reference: PMID:16218467
reference_title: "Cardiac involvement in systemic lupus erythematosus."
supports: REFUTE
snippet: Pericarditis is the most common cardiac abnormality in systemic lupus erythematosus (SLE) patients...
explanation: The literature states that pericarditis is the most common cardiac abnormality in SLE patients, not occasional.
- reference: PMID:31507126
reference_title: "The Heart Matters: Contribution of Genetic Factors in Recurrent Pericarditis."
supports: REFUTE
snippet: Several diseases are frequently associated with such manifestations. They include systemic lupus erythematosus...
explanation: The literature indicates that systemic lupus erythematosus is frequently associated with pericarditis, not occasionally.
- reference: PMID:33216192
reference_title: "[Pericarditis is inflammation of the pericardium, which rheumatologists should know]."
supports: REFUTE
snippet: Pericarditis can be present in the context of systemic inflammatory rheumatic diseases...
explanation: The literature suggests that pericarditis can commonly be present in systemic inflammatory rheumatic diseases, including SLE.
phenotype_term:
preferred_term: Pericarditis
term:
id: HP:0001701
label: Pericarditis
- category: Pulmonary
frequency: OCCASIONAL
name: Pleuritis
notes: Inflammation of the pleura (lining around the lungs)
evidence:
- reference: PMID:8153398
reference_title: "Pleuropulmonary manifestations of systemic lupus erythematosus."
supports: PARTIAL
snippet: The pleuropulmonary manifestation of systemic lupus erythematous (SLE) are pleuritis, acute lupus pneumonitis, chronic interstitial lung disease with fibrosis, alveolar hemorrhage, respiratory muscle and diaphragmatic dysfunction, atelectasis, bronchiolitis obliterans, pulmonary vascular disease with pulmonary hypertension, and pulmonary embolism.
explanation: The article explicitly lists pleuritis as one of the pleuropulmonary manifestations of SLE.
- reference: PMID:25318967
reference_title: "Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis."
supports: PARTIAL
snippet: We investigated the clinical characteristics of pleural effusion in systemic lupus erythematosus (SLE). A prospective analysis of 17 SLE patients with pleural effusion (seven lupus pleuritis, eight transudative effusions and two parapneumonic effusions) was performed.
explanation: The prospective analysis found lupus pleuritis in SLE patients, supporting the statement.
- reference: PMID:12055395
reference_title: "Diagnosis and management of lupus pleuritis."
supports: PARTIAL
snippet: Fortunately, pleuritis in systemic lupus erythematosus is not usually as life threatening as may be the renal or central nervous system complications. Nevertheless, pleuritis does occur in systemic lupus erythematosus and may be a significant cause of morbidity.
explanation: The article confirms that pleuritis occurs in SLE patients.
phenotype_term:
preferred_term: Pleuritis
term:
id: HP:0002102
label: Pleuritis
- category: Neuropsychiatric
frequency: OCCASIONAL
name: Seizures
evidence:
- reference: PMID:33626435
reference_title: "Seizures in systemic lupus erythematosus: A scoping review."
supports: PARTIAL
snippet: The prevalence of explicit episodes of seizures among SLE patients, varies from 2 to 8%.
explanation: The prevalence range of 2 to 8% suggests that seizures are not very common but occur at a noticeable rate, which could be interpreted as occasional.
- reference: PMID:12136236
reference_title: "SLEB3 in systemic lupus erythematosus (SLE) is strongly related to SLE families ascertained through neuropsychiatric manifestations."
supports: PARTIAL
snippet: Seizures and psychosis are neuropsychiatric (NP) manifestations of a large number of systemic lupus erythematosus (SLE) patients.
explanation: This reference supports the idea that seizures are a recognized neuropsychiatric manifestation of SLE, implying they occur with some regularity.
phenotype_term:
preferred_term: Seizures
term:
id: HP:0001250
label: Seizure
- category: Neuropsychiatric
frequency: OCCASIONAL
name: Psychosis
evidence:
- reference: PMID:30375754
reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
supports: PARTIAL
snippet: Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status.
explanation: The study indicates that psychosis is an infrequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), which suggests it is not common but does occur occasionally. This partially supports the statement that psychosis is an 'occasional' manifestation.
- reference: PMID:37771217
reference_title: "Psychosis Unmasking a Diagnosis of Systemic Lupus Erythematosus: a Case Report."
supports: PARTIAL
snippet: Psychosis is a rare NPSLE manifestation that can occur at any phase of the illness; 21% of SLE-related psychosis cases occur at the onset of SLE.
explanation: This case report describes psychosis as a rare manifestation of NPSLE, occurring in 21% of cases at the onset of SLE. While 'rare' and 'occasional' are not identical, they both imply infrequency, partially supporting the statement.
phenotype_term:
preferred_term: Psychosis
term:
id: HP:0000709
label: Psychosis
biochemical:
- name: Anti-Nuclear Antibodies (ANA)
specificity: High
frequency: 98%
presence: Positive
evidence:
- reference: PMID:32884126
reference_title: "New insights into the role of antinuclear antibodies in systemic lupus erythematosus."
supports: PARTIAL
snippet: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction.
explanation: While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature.
- reference: PMID:34996081
reference_title: "Anti-Nuclear Antibody Quantitation: Calibration and Harmonization Adjustment via Population Interrogation."
supports: PARTIAL
snippet: The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent.
explanation: The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate.
- reference: PMID:23456415
reference_title: "Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital."
supports: PARTIAL
snippet: Antinuclear antibody was present in 79.6%.
explanation: This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE.
- reference: PMID:22301032
reference_title: "Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody."
supports: PARTIAL
snippet: Based on some research evidence and consensus, the diagnosis of pSLE is unlikely if the ANA is negative, and most patients with SLE have a positive ANA at a titer ≥1:160
explanation: While the statement indicates the common presence of ANA in SLE, it does not confirm the 98% figure.
- name: Anti-dsDNA Antibodies
specificity: High
presence: Positive
evidence:
- reference: PMID:29224677
reference_title: "Diagnostic and prognostic tests in systemic lupus erythematosus."
supports: PARTIAL
snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens.
explanation: This supports the presence of anti-dsDNA antibodies in patients with SLE.
- reference: PMID:20414746
reference_title: "Glomerular antibodies in lupus nephritis."
supports: PARTIAL
snippet: Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN.
explanation: This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis.
- reference: PMID:35049409
reference_title: "IgA anti-dsDNA antibodies: A neglected serological parameter in systemic lupus erythematosus."
supports: SUPPORT
snippet: Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE).
explanation: This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE.
- reference: PMID:2203596
reference_title: "Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus."
supports: SUPPORT
snippet: The prevalence of anti-dsDNA antibodies was strongly influenced by the selection criteria of the patient.
explanation: This indicates that anti-dsDNA antibodies are present in SLE patients, even though their prevalence can vary based on specific criteria.
- name: Anti-Smith Antibodies
specificity: High
presence: Positive
evidence:
- reference: PMID:29503043
reference_title: "Origins and specificity of auto-antibodies in Sm+ SLE patients."
supports: SUPPORT
snippet: One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE.
explanation: The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity.
- name: Anti-Histone Antibodies
notes: Common in drug-induced lupus.
presence: Positive
evidence:
- reference: PMID:35383534
reference_title: "Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus."
supports: SUPPORT
snippet: Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE).
explanation: The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus.
- reference: PMID:35383534
reference_title: "Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus."
supports: PARTIAL
snippet: AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs.
explanation: While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents.
genetic:
- name: HLA-DR2
presence: Positive
evidence:
- reference: PMID:37801591
reference_title: "HLA-DR genotypes in patients with systemic lupus erythematosus in Taiwan."
supports: PARTIAL
snippet: HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis)
explanation: The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population.
- name: HLA-DR3
presence: Positive
evidence:
- reference: PMID:17910142
reference_title: "Antinuclear antibodies and HLA class II alleles in Jamaican patients with systemic lupus erythematosus."
supports: PARTIAL
snippet: A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01).
explanation: The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE.
- reference: PMID:6103441
reference_title: "Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility."
supports: NO_EVIDENCE
snippet: It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE.
explanation: This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE.
- name: PTPN22
association: Associated
evidence:
- reference: PMID:31232672
reference_title: "PTPN22 Gene Polymorphisms in Pediatric Systemic Lupus Erythematosus."
supports: SUPPORT
snippet: We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p < 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE.
explanation: The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE.
- name: STAT4
association: Associated
evidence:
- reference: PMID:23912645
reference_title: "Association of STAT4 rs7574865 with susceptibility to systemic lupus erythematosus in Iranian population."
supports: SUPPORT
snippet: Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE.
explanation: The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE.
- reference: PMID:31082500
reference_title: "Investigation of systemic lupus erythematosus (SLE) with integrating transcriptomics and genome wide association information."
supports: SUPPORT
snippet: Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4...
explanation: This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data.
- reference: PMID:34525002
reference_title: "Genetic Polymorphisms in Patients With Systemic Lupus Erythematosus and Jaccoud Arthropathy: A Pilot Study."
supports: NO_EVIDENCE
snippet: 'The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in Salvador, Bahia, Brazil.'
explanation: The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE.
- name: IRF5
association: Associated
notes: Interferon regulatory factor 5; transcription factor driving type I interferon pathway activation
evidence:
- reference: PMID:20962850
reference_title: "A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles."
supports: SUPPORT
snippet: Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE...
explanation: The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE.
- reference: PMID:26233721
reference_title: "Association of the IRF5 rs2070197 polymorphism with systemic lupus erythematosus: a meta-analysis."
supports: SUPPORT
snippet: This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE...
explanation: The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations.
- reference: PMID:23251221
reference_title: "Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus."
supports: SUPPORT
snippet: Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis.
explanation: The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease.
- reference: PMID:20453440
reference_title: "Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases."
supports: SUPPORT
snippet: Recent large-scale studies in the Caucasian populations identified many new susceptibility genes to systemic lupus erythematosus (SLE)... In IRF5, the risk haplotype in Caucasians was not present in Japanese... All of these genes were associated with SLE...
explanation: The study confirms that IRF5 is associated with SLE in both Caucasian and Japanese populations.
- reference: PMID:36245280
reference_title: "Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus."
supports: SUPPORT
snippet: IRF5 plays a crucial role in the development of lupus... Genome-wide association studies have identified several systemic lupus erythematosus (SLE) risk single-nucleotide polymorphisms (SNPs) enriched in the IRF5 locus.
explanation: The study identifies IRF5 as playing a key role in SLE development with confirmed risk SNPs.
- name: TLR7
association: Associated
notes: Toll-like receptor 7; B cell-intrinsic driver promoting RNA-associated autoantibodies and disease activity
- name: TLR9
association: Associated
notes: Toll-like receptor 9; can exert counter-regulatory effects, restraining age-associated B cell differentiation
- name: MYD88
association: Associated
notes: Myeloid differentiation primary response 88; adaptor protein downstream of TLR7/9 required for autoantibody production
- name: CYBB
association: Associated
notes: Cytochrome b-245 beta chain (NOX2); NOX2-generated ROS negatively regulate TLR7 signaling; loss exacerbates disease
- name: TNFSF13B
association: Associated
notes: TNF superfamily member 13b (BAFF); supports B cell survival and extrafollicular responses integrated with IFN/Tfh circuits
- name: IL21
association: Associated
notes: Interleukin 21; Tfh-derived cytokine driving B cell differentiation to plasma cells
- name: BACH2
association: GWAS
notes: Transcription factor regulating Treg/effector T cell balance and B cell class switching
- name: TNFAIP3
association: GWAS
notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: STAT3
association: GWAS
notes: Signal transducer mediating Th17 differentiation via JAK-STAT pathway
- name: IL10
association: GWAS
notes: Anti-inflammatory cytokine critical for immune tolerance
- name: EGR2
association: GWAS
notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: ETS1
association: GWAS
notes: Transcription factor regulating T and B cell development and immune cell differentiation
- name: IRF4
association: GWAS
notes: Transcription factor essential for Th17 and Th2 cell differentiation and plasma cell development
- name: IRF8
association: GWAS
notes: Interferon regulatory factor controlling myeloid cell development and type I interferon response
- name: IKZF1
association: GWAS
notes: Ikaros transcription factor essential for lymphocyte development and differentiation
- name: SMAD3
association: GWAS
notes: TGF-beta signaling mediator regulating T cell differentiation and immune tolerance
- name: REL
association: GWAS
notes: NF-kB subunit c-Rel controlling lymphocyte activation and survival
- name: PRDM1
association: GWAS
notes: Blimp-1 transcription factor regulating T cell and B cell terminal differentiation
environmental:
- name: UV Exposure
notes: Exacerbates disease activity.
presence: Positive
evidence:
- reference: PMID:24763542
reference_title: "Ultraviolet radiation and systemic lupus erythematosus."
supports: SUPPORT
snippet: While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE.
explanation: The literature clearly states that UV radiation exposure may exacerbate pre-existing lupus, which supports the statement.
- reference: PMID:22385883
reference_title: "Seasonal variations of systemic lupus erythematosus flares in southern France."
supports: SUPPORT
snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
explanation: The study investigates the seasonal variation in lupus flares and correlates increased flares with increased temperature and sunshine, supporting the statement that UV exposure exacerbates disease activity.
exposure_term:
preferred_term: UV light exposure
term:
id: ECTO:0000006
label: exposure to ultraviolet radiation
- name: Infection
notes: Can trigger or worsen disease symptoms.
presence: Positive
evidence:
- reference: PMID:36332998
reference_title: "Systemic Lupus Erythematosus Risk: The Role of Environmental Factors."
supports: PARTIAL
snippet: This review focuses on SLE risk potentially associated with environmental factors including infections.
explanation: The paper identifies infections as one of the environmental factors potentially associated with the risk of SLE, thereby supporting the statement that infections can trigger or worsen disease symptoms in SLE.
- reference: PMID:25022358
reference_title: "Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome."
supports: SUPPORT
snippet: New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described.
explanation: This review mentions infections, specifically Epstein-Barr virus, as triggers for autoimmunity, which supports the notion that infections can influence SLE disease activity.
- reference: PMID:38146370
reference_title: "Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus."
supports: PARTIAL
snippet: The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated.
explanation: This study supports the connection between infections (specifically EBV) and SLE, further establishing that infections can trigger or worsen SLE symptoms.
exposure_term:
preferred_term: Infectious agent exposure
term:
id: ECTO:3000000
label: exposure to organism
- name: Stress
notes: Psychological stress can trigger flares.
presence: Positive
evidence:
- reference: PMID:25216337
reference_title: "Environmental factors, toxicants and systemic lupus erythematosus."
supports: PARTIAL
snippet: It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals
explanation: This reference discusses various environmental factors that can trigger SLE flares, which supports the notion that stress, as an environmental factor, can do so as well.
- reference: PMID:36537191
reference_title: "Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort."
supports: SUPPORT
snippet: In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined.
explanation: This reference directly supports the statement that psychological stress can trigger and worsen SLE flares.
- reference: PMID:36535611
reference_title: "The link between post-traumatic stress disorder and systemic lupus erythematosus."
supports: PARTIAL
snippet: Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE.
explanation: This reference indicates a link between stress-related disorders and the development or worsening of SLE.
exposure_term:
preferred_term: Psychological stress exposure
animal_models:
- species: Mouse
genes:
- preferred_term: FAS
term:
id: hgnc:11920
label: FAS
genotype: MRL/lpr strain
alleles:
- FAS lpr
description: genetically prone to develop lupus-like symptoms and APS
evidence:
- reference: PMID:25183233
reference_title: "Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model."
supports: SUPPORT
snippet: Mouse models of autoimmunity, such as (NZB×NZW)F1, MRL/MpJ-Fas(lpr) (MRL-lpr) and BXSB mice, spontaneously develop systemic lupus erythematosus (SLE)-like syndromes with heterogeneity and complexity that characterize human SLE
explanation: This excerpt supports the statement by confirming that MRL/MpJ-Fas(lpr) (MRL-lpr) mice develop SLE-like syndromes.
- reference: PMID:14550881
reference_title: "HLA class II alleles and genetic predisposition to the antiphospholipid syndrome."
supports: NO_EVIDENCE
snippet: The association of HLA-DR4, -DR7, -DRw53 and -DQB1*0302 with aCL... can also be found in SLE...
explanation: This excerpt supports the statement, indicating that there is an association between HLA alleles and SLE in MRL-lpr mice.
- reference: PMID:38113962
reference_title: "Fas(lpr) gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus."
supports: SUPPORT
snippet: Sle1 and Faslpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus
explanation: The snippet confirms that Fas(lpr) is a lupus susceptibility locus leading to SLE manifestations.
- reference: PMID:28078597
reference_title: "CD95 and the MRL-lpr Mouse Model."
supports: SUPPORT
snippet: This is characterized by the development of arthritis and immune complex glomerulonephrosis making this strain a useful model for studying systemic lupus erythematosus.
explanation: This excerpt supports the statement by describing the MRL-lpr strain as a useful model for studying SLE, noting the development of relevant symptoms.
- reference: PMID:18325838
reference_title: "Accelerated atherosclerosis in ApoE deficient lupus mouse models."
supports: PARTIAL
snippet: breeding the ApoE(-/-) defect onto MRL/lpr mice all caused a modest increase of atherosclerosis...
explanation: This excerpt partially supports the statement, indicating that breeding the ApoE(-/-) defect into MRL/lpr mice results in an increase in atherosclerosis (related to APS). However, it does not explicitly conclude a genetic predisposition to APS.
- species: Mouse
background: (NZB/BlNJ x NZW/LacJ)F1/J
evidence:
- reference: PMID:36211391
reference_title: "(NZW × BXSB) F1 male mice: An unusual, severe and fatal mouse model of lupus erythematosus."
supports: PARTIAL
snippet: The (NZW×BXSB) F1 lupus-prone male mouse model of this disease is potentially useful to study mechanism and treatment modalities, but there is a lack of information about this model's characterization and disease progression
explanation: The reference discusses the (NZWxBXSB) F1 model rather than the (NZB/BlNJ x NZW/LacJ) F1/J model.
- reference: PMID:31943822
reference_title: "DNA Vaccination With Hsp70 Protects Against Systemic Lupus Erythematosus in (NZB × NZW)F1 Mice."
supports: SUPPORT
snippet: 'METHODS: Lupus-prone (NZB × NZW)F1 mice that had been DNA-vaccinated with plasmids encoding Hsp70 and controls were monitored for lupus disease parameters including anti-double stranded DNA (anti-dsDNA) autoantibodies and cytokines using enzyme-linked immunosorbent assay, and for kidney function and pathology'
explanation: This reference supports the use of (NZB x NZW)F1 mice as a model for SLE.
treatments:
- name: Type I Interferon Receptor Antagonist
description: Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: anifrolumab
term:
id: NCIT:C166658
label: Anifrolumab
notes: Anifrolumab approved for moderate-to-severe SLE; biomarker-guided therapy
evidence:
- reference: PMID:28130918
reference_title: "Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus."
supports: SUPPORT
snippet: Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE
explanation: This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures.
- name: B Cell Depletion Therapy
description: Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
notes: CAR-T cell therapy has induced drug-free remissions in early clinical experiences
- name: BAFF Pathway Inhibition
description: Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: belimumab
term:
id: NCIT:C91385
label: Belimumab
notes: Integrates BAFF/IFN biomarkers with therapeutic selection
evidence:
- reference: PMID:22127708
reference_title: "A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus."
supports: SUPPORT
snippet: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE
explanation: This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo.
- name: Immunosuppressive Therapy
description: Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
notes: Standard immunosuppressive agents for disease control
- name: Supportive Care
description: Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
notes: Organ-specific symptomatic management
review_notes: "SLE is a complex autoimmune disorder that can affect multiple organ systems.\nThe hallmark is production of autoantibodies. Diagnosis requires a combination \nof clinical findings and positive antibody tests (ANA, anti-dsDNA, anti-Sm).\nFrequency of involvement of each organ system is variable. Renal and CNS involvement\nare major sources of morbidity. Disease course is characterized by periods of \nflare and remission."
disease_term:
preferred_term: systemic lupus erythematosus
term:
id: MONDO:0007915
label: systemic lupus erythematosus
classifications:
harrisons_chapter:
- classification_value: musculoskeletal system disorder
- classification_value: connective tissue disease
- classification_value: autoimmune disease